A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Inclusion Criteria: * Adult patients, 40 to 70 years of age (inclusive) at screening * Patients with Type 2 diabetes mellitus diagnosed at least 12 weeks before screening and either drug-naïve or treated with stable metformin monotherapy for at least 12 weeks prior to screening * HbA1c \>/= 7 % and \</= 9% at screening * Absence of history of coronary artery disease Exclusion Criteria: * Diagnosis or history of Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes * Current treatment with fibrates, thiazolidinediones, or insulin * Prior intolerance to thiazolidinediones and/or fibrates * Clinically significant liver disease or impaired liver function * Know chronic diabetic complications (i.e. retinopathy, neuropathy, nephropathy) * Symptomatic congestive heart failure classified as NYHA class II-IV * Diagnosed and/or treated malignancy within the past 5 years, except for treated basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer * Contraindications to MRI, or inability to tolerate MRI scanning